Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series.

Journal of the National Comprehensive Cancer Network : JNCCN - 29 Aug 2023

Strelnikov Jacob, Zhou Alice, Butt Omar, Ansstas Michael, Ansstas George

Abstract excerpt

Targeted and immune therapies have changed the paradigm of treatment for patients with metastatic melanoma. Treatment of patients with symptomatic melanoma brain metastases, however, is complicated by the frequent use of immune suppression for the management of vasogenic edema and the urgency in addressing disease burden. Use of BRAF/MEK inhibitors in patients with a corresponding BRAF V600 mutation often results...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 37647938
DOI: 10.6004/jnccn.2023.7032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series.PMID 37647938Read ↗

Melanoma brain metastasis: overview of current management and emerging targeted therapies.Semantic proximity Read ↗

Systemic therapies for melanoma brain metastases: which drug for whom and when?Semantic proximity Read ↗

Impact of BRAF inhibitors on surgical outcomes in melanoma brain metastases: Evidence from a multicenter observational study.Semantic proximity Read ↗

BRAF-MEK inhibition in melanoma brain metastases: a new hope.Semantic proximity Read ↗

Management of V600E and V600K BRAF-Mutant Melanoma.Semantic proximity Read ↗

Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.Semantic proximity Read ↗

Rapid hyperacute intracranial deterioration following initiation of ipilimumab/nivolumab in BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case series.Semantic proximity Read ↗

Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice.Semantic proximity Read ↗

Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing?Semantic proximity Read ↗

Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

Treating metastatic melanoma in 2014: what just happened and what is next?Semantic proximity Read ↗

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.